Insights Unwrapped

The Sound of *Trump-ets*



9th November 2024

SPRC Research

ТМ

Trump and Biden: The National Debt

		PPROVED BY PRES	Trillions of Dollars		TEN-
\$10T —				\$10T —	
\$8T —	Other Legislation Health Executive Actions			\$8T —	
ФОТ	ACA Tax Delays & Repeals			<u>۵</u> ٥١ —	
\$6T —	Bipartisan Budget Acts of 2018 & 2019			\$6т —	
<u></u> ФО1 ——			CO VI	<i>ф</i> от —	Other
\$4T —	Tax Cuts & Jobs Act		30 41		Stud
			YUITI	\$4T —	Bipartisa
	Other COVID Relief		NET TEN-YEAR DEBT APPROVED		Appropriat
\$2T —	Response & Relief Act		BY PRESIDENT TRUMP	\$2T —	
	CARES Act				Amerio
\$от —		Tariffs		\$от —	
	TEN-YEAR DEBT INCREASE	TEN-YEAR DEBT REDUCTION			TEN-YE

Source: www.crfb.org/papers/trump-and-biden-national-debt

President Trump approved \$8.4 trillion of new ten-year borrowing during his full term in office (including \$3.6 trillion for CARES Act and other COVID relief). President Biden had approved \$4.3 trillion of new ten-year borrowing (including \$2.1 trillion for American Rescue Plan Act).



AR DEBT APPROVED BY **PRESIDENT BIDEN**

Trillions of Dollars




en (January 20, 2021-June 21, 2024)



Status Quo on Tariffs Post Trump 1.0

US-China Trade Tariffs




2024

The Biden administration had retained the tariffs imposed by the preceding Trump administration, though Trump previously proposed a significant increase in tariffs to 60%. SPROU Research

ΤМ

Post Pandemic Economic Performance




The economy experienced a sharp downturn during the COVID-19 pandemic as many businesses shut down. Under Trump, it rebounded strongly, outperforming many other Western economies in its recovery.

This trend has continued under President Biden, with the U.S. achieving the strongest pandemic recovery among G7 countries, as measured by GDP growth.



Higher US Inflation in Biden's Term




Inflation has been markedly higher during the Biden administration, rising 20.1% over the first 45 months (an annualized rate of 5.4%) compared to a 7.1% increase over the same period in Trump's term (annualized at 1.9%), according to the government's Consumer Price Index.

Inflation peaked at 9% in 2022, a 40year high, which Biden attributed partly to COVID-19's effects and the Russia-Ukraine conflict amid global inflation trends.




US Border Control



The Trump administration implemented strict border policies, while the Biden administration pledged a more "humane" approach.



Inflation and Yields: What likely ahead?



Note: Top 20 items among 72 subcomponetns of core CPI goods prices which showed the largest positive deviation from trend since tariffs were implemented. Those 20 items account for 17% of total core CPI goods prices

Source: BLS, Haver, Nomura

• A second Trump term with increased tariffs could add further **inflationary pressure** beyond the levels seen with the 2018-2019 trade restrictions.

• If Trump raises import duties or cuts corporate taxes, inflation and government borrowing may rise, **pushing U.S. yields higher.** While the Fed may cut short-term rates, long-term yields are market-driven and rise due to inflation expectations. <u>Higher yields and a</u> stronger dollar could harm Indian equities and emerging markets as investors shift to safer U.S. assets. Monitoring the dollar and yields is essential.

DISCLAIMER

This report has been prepared by Research Analyst and is solely for information of the recipient only. The report must not be used as a singular basis of any investment decision. The views herein are of a general nature and do not consider the risk appetite or the particular circumstances of an individual investor; readers are requested to take professional advice before investing. Nothing in this document should be construed as investment advice.

Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in securities of the companies referred to in this document (including merits and risks) and should consult their own advisors to determine merits and risks of such investment. The information and opinions contained herein have been compiled or arrived at, based upon information obtained in good faith from sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. Descriptions of any company or companies or their securities mentioned herein are not intended to be complete. Research Analyst is not obliged to update this report for such changes. Research Analyst has the right to make changes and modifications at any time.

This report is not directed to, or intended for display, downloading, printing, reproducing or for distribution to or use by, any person or entity who is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, reproduction, availability or use would be contrary to law or regulation or what would subject Research Analyst or its affiliates to any registration or licensing requirement within such jurisdiction. If this report is inadvertently sent or has reached any person in such country, especially, United States of America, the same should be ignored and brought to the attention of the sender. This document may not be reproduced, distributed or published in whole or in part, directly or indirectly, for any purposes or in any manner.

It should not be considered to be taken as an offer to sell or a solicitation to buy any security. This document is not, and should not, be construed as an offer or solicitation of an offer, to buy or sell any securities or other financial instruments. This report should not be construed as an invitation or solicitation to do business with Research Analyst. Research Analyst do not take any responsibility, financial or otherwise, of the losses or the damages sustained due to the investments made or any action taken on basis of this report.

TRUDENCE CAPITAL ADVISORS PRIVATE LIMITED Trade Name: TRUDENCE CAPITAL Registration No.: INH000015747 CIN: U73200MH2024PTC417356 Registered office Address: FLT NO 63 1 F CTS NO. 168, KALPATARU, AURA BLDG, LBS MARG OPP R CITY MALL, MUMBAI, MAHARASHTRA, 400086 Contact No: 8224900841 Email Id: nitin@iiinsight.com Compliance Officer: Nitin Mangal Contact No: 8224900841 Email Id: nitin@iiinsight.com Grievance Officer: Nitin Mangal Contact No: 8224900841 Email ID: nitin@iiinsight.com

Standard warning

"Investment in securities market are subject to market risks. Read all the related documents carefully before investing."

Disclaimers

"Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors"



Content Compiled in Collaboration with Sprout Partners Pvt. Ltd. https://www.sproutpartners.in/